Amicus Therapeutics, Inc. (FOLD)
Automate Your Wheel Strategy on FOLD
With Tiblio's Option Bot, you can configure your own wheel strategy including FOLD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol FOLD
- Rev/Share 1.7652
- Book/Share 0.6291
- PB 9.0769
- Debt/Equity 2.2911
- CurrentRatio 3.341
- ROIC 0.5532
- MktCap 1758286010.0
- FreeCF/Share 0.0052
- PFCF 1093.4614
- PE -59.8136
- Debt/Assets 0.5615
- DivYield 0
- ROE -0.1681
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | FOLD | Morgan Stanley | Overweight | Equal Weight | $17 | $12 | Dec. 13, 2024 |
| Initiation | FOLD | Jefferies | -- | Buy | -- | $18 | Sept. 6, 2024 |
News
U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association
Read More
The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy
Published: June 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Physician group filed an amicus brief in Chiles v. Salazar defending the right of licensed therapists to offer "conversion therapy" in gender dysphoria.
Read More
Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma
Published: June 12, 2025 by: Seeking Alpha
Sentiment: Positive
Amicus Therapeutics is a commercial-stage biotech with a focused pipeline in Fabry, Pompe, and rare kidney diseases. Galafold, its lead therapy, is the only approved oral treatment for Fabry disease and is driving consistent revenue growth. Key growth drivers for Galafold include expanding patient reach, new markets, increased market share, and high patient adherence.
Read More
New Strong Sell Stocks for June 3rd
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Negative
FOLD, BRCC and VLVLY have been added to the Zacks Rank #5 (Strong Sell) List on May 3, 2025.
Read More
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) in Muscle and Nerve . In this new publication, based on a within group effect-size analysis, subjects who switched from alglucosidase alfa to cipa+mig achieved improvements or stability in most of the outcomes measured.
Read More
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Negative
Amicus' first-quarter 2025 earnings and sales miss estimates. Shares decline.
Read More
Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.02 per share a year ago.
Read More
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025.
Read More
4 Healthcare Stocks to Buy as the Sector Faces Government Heat
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.
Read More
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
Read More
Amicus Therapeutics (FOLD) Up 0.1% Since Last Earnings Report: Can It Continue?
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
Read More
NCLA Amicus Brief Asks Fifth Circuit to Maintain Block Against Corporate Transparency Act
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al. Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al.
Read More
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March.
Read More
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Negative
Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.
Read More
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm
Published: February 19, 2025 by: Business Wire
Sentiment: Neutral
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company's shareholders. Click here for additional information: https://kaskelalaw.com/case/amicus-therapeutics/ Since December 2023, shares of Amicus' common stock have declined in value from a trading price of $14.50 per share to a current trading price of approximately $11.00 per share, a decline of nearly 25% in value. The investigation seeks.
Read More
Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q4 2024 Earnings Conference Call February 19, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President and Chief Executive Officer Sebastien Martel - Chief Business Officer Jeffrey Castelli - Chief Development Officer Simon Harford - Chief Financial Officer Conference Call Participants Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Dennis Ding - Jefferies Joe Schwartz - Leerink Partners Kristen Kluska - Cantor Fitzgerald Malcolm Kuno - JPMorgan Salveen Richter - Goldman Sachs Gil Blum - Needham & Company Jeff Hung - Morgan Stanley Joshua …
Read More
Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.11 per share a year ago.
Read More
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J.
Read More
Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm
Published: February 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amicus Therapeutics, Inc. (NASDAQ: FOLD) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Read More
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024.
Read More
About Amicus Therapeutics, Inc. (FOLD)
- IPO Date 2007-05-31
- Website https://amicusrx.com
- Industry Biotechnology
- CEO Mr. Bradley L. Campbell M.B.A.
- Employees 499